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Aims To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality
in patients with heart failure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
An AF genetic risk score was calculated in 3759 European ancestry individuals (1783 with sinus rhythm, 1976 with
AF) from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) by summing 97 single
nucleotide polymorphism (SNP) alleles (ranging from 0–2) weighted by the natural logarithm of the relative SNP risk
from the latest AF genome-wide association study. Further, we assessed AF risk variance explained by additive SNP
variation, and performance of clinical or genetic risk factors, and the combination in classifying AF prevalence. AF was
classified as AF or atrial flutter (AFL) at baseline electrocardiogram and/or a history of AF or AFL. The genetic risk
score was associated with AF after multivariable adjustment. Odds ratio for AF prevalence per 1-unit increase genetic
risk score was 2.12 (95% confidence interval 1.84–2.45, P = 2.15× 10−24) in the total cohort, 2.08 (1.72–2.50,
P = 1.30× 10−14) in heart failure with reduced ejection fraction (HFrEF) and 2.02 (1.37–2.99, P = 4.37×10−4) in heart
failure with preserved ejection fraction (HFpEF). AF-associated loci explained 22.9% of overall AF SNP heritability.
Addition of the genetic risk score to clinical risk factors increased the C-index by 2.2% to 0.721.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions The AF genetic risk score was associated with increased AF prevalence in HFrEF and HFpEF. Genetic variation
accounted for 22.9% of overall AF SNP heritability. Addition of genetic risk to clinical risk improved model
performance in classifying AF prevalence.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Atrial fibrillation • Heart failure • Genetic association studies • Single nucleotide polymorphism •
Risk factors
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and
is highly prevalent in patients with heart failure.1–3 The co-existence
of these conditions can be expected by virtue of their prevalence
alone: the lifetime risk of developing AF is about one in three in
individuals of European ancestry and one in five in individuals of
African ancestry,4–6 and after age 45 the lifetime risk of heart failure
ranges between 20–45%.7
Furthermore, both conditions have many shared risk factors
which makes their co-existence more likely.8,9 Additionally, a recip-
rocal relation between both conditions seems to exist, but regard-
less of which condition occurs first, the concomitant presence of
both AF and heart failure is associated with substantially increased
risks of mortality.2,3
Atrial fibrillation is common in heart failure and prevalence of
the arrhythmia increases with heart failure severity, but little is
known about the mechanisms that underlie AF onset in heart
failure patients.10,11 Genetic factors could theoretically explain,
at least partly, the increased risk of AF in patients with heart
failure.12 But heritability of AF is complex; in a recent study,
97 genome-wide susceptibility loci for AF were identified, and
the proportion of heritability explained by the loci in individ-
uals of European ancestry was 42%.13 Prevalence estimates of
heart failure in population-based biobanks and case-referent stud-
ies used for AF genome-wide association studies (GWAS) is lim-
ited, and it remains unclear whether individuals with AF in the
context of heart failure share a similar genetic susceptibility to the
arrhythmia.
We aimed to study the association between a genetic risk
score based on 97 lead single nucleotide polymorphisms
(SNPs)13 with prevalent AF and all-cause mortality in a large
sample of patients with heart failure included in The BIOl-
ogy Study to TAilored Treatment in Chronic Heart Failure
(BIOSTAT-CHF) . Further, we assessed the variance in AF
prevalence explained by additive SNP variation (SNP heritabil-
ity), and determined the discriminatory accuracy of clinical risk
factors, genetic risk factors, and the combination in classifying
AF prevalence.
Methods
Study population
The prospective, observational, international BIOSTAT-CHF study
included 2516 patients with heart failure from 11 European coun-
tries between December 2010 and December 2012. Another 1738
patients from Scotland were included in a validation cohort between
October 2010 and April 2014. The rationale, design, and primary
results have been previously published.14 Briefly, the majority of
patients were hospitalized for acute heart failure, and the remain-
der presented with worsening signs and/or symptoms of heart fail-
ure at outpatient clinics. Patients had to have objective evidence
of cardiac dysfunction documented either by left ventricular ejec-
tion fraction (LVEF) of ≤40%, previous heart failure hospitalization,
or plasma concentrations of B-type natriuretic peptide (BNP) and/or
N-terminal pro-B-type natriuretic peptide (NT-proBNP) >400 pg/mL ..
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Figure 1 Flowchart of the final BIOSTAT-CHF study popula-
tion. AF, atrial fibrillation; ECG, electrocardiogram; HFpEF, heart
failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; PM, pacemaker; SNP, single nucleotide
polymorphism; SR, sinus rhythm.
or> 2000 pg/mL, respectively. According to study design, all patients
used diuretics but were not on optimal, evidence-based medical ther-
apy of angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers and, or beta-blockers. After inclusion patients were exten-
sively phenotyped and genotyped, underwent physical examination and
quality of life measurements, and plasma, serum, and urine samples
were collected for analysis. During the first 3months of follow-up,
medication was optimized. The study complies with the Declaration of
Helsinki, medical ethics committee of participating centres approved
the study, and all patients provided written informed consent before
inclusion.
Patient selection
For the current analysis the BIOSTAT-CHF index cohort (n = 2516)
and validation cohort (n =1738) were combined to achieve a larger
set of patients (n = 4254). Patients with no blood samples available for
genotyping (n = 166), self-reported non-European ancestry (n = 37),
and pacemaker rhythm or missing variables that prohibited rhythm
classification (n = 292) were excluded (Figure 1).
Atrial fibrillation prevalence
and all-cause mortality
Atrial fibrillation prevalence was defined as clinical history of AF or
atrial flutter (AFL) and/or AF(L) on baseline electrocardiogram (ECG).
Patients were regarded as having sinus rhythm if they had no history of
AF and sinus rhythm on baseline ECG. Incident AF was not captured
during follow-up.
After the optimization (3 months) and maintenance phase
(6 months),14 patients were followed by standard clinical follow-up
or telephone contact with 6-month intervals. Follow-up ended on
April 1st 2015. Median follow-up duration was approximately
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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21months. During follow-up all deaths and hospitalizations were
recorded. For the current analysis, all-cause mortality was assessed.
Genotyping in BIOSTAT-CHF
The two cohorts were processed, genotyped, QC’d and imputed
independently, using the same protocols. Genotyping of all patients
from both BIOSTAT-CHF cohorts was performed using the Affymetrix
Axiom Genome-Wide UKBWCSG genotyping array. Sample level QC
was performed for X chromosome homozygosity (sex mismatch) and
identity by descent (IBD) estimates (relatedness and duplicates). Prior
to imputation, variants were removed if their call rate was <95% for
variants with minor allele frequency (MAF) ≥5%, or< 99% for variants
with MAF <5%, or had a Hardy–Weinberg equilibrium P <1x10−6.
Imputation was performed using SHAPEIT215 and IMPUTE216 with the
phase 3 release 1000G reference panel.17
Genetic analysis
Atrial fibrillation genetic risk score
Genotypes of 97 SNPs associated with AF risk in the latest published
GWAS13 with significance thresholds of P <1×10−8 were used to
calculate an individual patient AF genetic risk score by summing
the dosage of each AF risk allele in BIOSTAT-CHF (ranging from
0–2) weighted by the natural logarithm of the relative risk for each
SNP. Weights were determined by the latest AF GWAS13 (online
supplementary Table S1). The SNP rs465276 was not available in
BIOSTAT-CHF and was substituted with a proxy (rs361834, r2 = 0.91,
based on pairwise linkage disequilibrium from European ancestry
samples in the Broad AF study13). All SNPs had an INFO score>0.4 and
a Hardy–Weinberg equilibrium P > 1×10−6. AF genetic risk scores
were calculated using PLINK v2.00.18
Proportion of heritability explained
We assessed the proportion of AF phenotypic variance explained by
additive genetic variation, otherwise referred to as SNP heritability
(h2g). h
2
g was calculated with the software BOLT-LMM v2.3.2.
19 The
AF loci were defined as a region of 1 Mb (±500 kb) around each of the
97 reported sentinel variants from the latest AF GWAS analysis.13 We
used the imputed genotype data, filtered the variants for imputation
quality>0.8, as calculated by QCTOOL v2,20 hard-called the genotypes
with a genotype probability threshold >0.9 with PLINK v2.00,18 and
combined the overlapping variants that remained from the index
and validation cohort of BIOSTAT-CHF. Additional filtering removed
variants with MAF <1% and variant call rate missingness >0.5%. We
then applied one round of pruning with the settings – indep-pairwise
50 5 0.9 in PLINK. The heritability calculation was performed on
the remaining 806130 variants. We included age, sex, and the first
five principal components as covariates. The observed heritability
estimates were converted to the liability scale following equation 17
from Lee et al.21 and using the AF prevalence in the BIOSTAT-CHF
cohorts (AF prevalence of 53%) as disease prevalence in a heart failure
population.
Statistical analyses
Normally distributed variables are depicted as means ± standard
deviation and non-normally distributed variables as median with the
first and third quartile (Q1, Q3). Categorical variables are presented ..
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.. as numbers with percentages. Multivariable logistic regression models
were used to examine whether a genetic risk score build of 97 AF
genetic loci was associated with AF prevalence. Model 1 was adjusted
for age, sex, and the first 10 principal components of ancestry. Model 2
was adjusted for clinical AF risk factors from the CHARGE-AF risk
model,22 a model aimed to predict future risk of AF. Variables include:
age, height, weight, systolic and diastolic blood pressure, current
smoking, hypertension as a proxy for antihypertensive treatment,
diabetes, myocardial infarction, and the first 10 principal components
of ancestry. The CHARGE-AF risk model variables heart failure and
race were not included since our population consists of European
ancestry patients with heart failure. A total of 96 patients had missing
values and were excluded. We calculated the area under the receiver
operating curve (AUC) in logistic regression models for AF prevalence.
All calculations included the first 10 principal components and were
performed in R using the package pROC23 to calculate the AUC and
the 95% confidence intervals (CI) with the DeLong method. Cox
proportional hazard analysis was performed to determine hazard ratios
(HR) with 95% CI for the genetic risk score and all-cause mortality.
All HR were adjusted for covariates of the CHARGE-AF risk model.
The Cox proportional hazards assumption was assessed by visually
inspecting plots of Schoenfeld residuals against time, which showed
no proportionality violation (i.e. the plots showed random patterns of
residuals against time). Interaction testing was performed to determine
whether the effect of the genetic risk score differed between the
heart failure phenotypes, with regard to AF prevalence and all-cause
mortality risk. Secondary analyses were performed in subgroups based
on LVEF: LVEF <40% and LVEF ≥50%, respectively, heart failure with
reduced ejection fraction (HFrEF) and heart failure with preserved
ejection fraction (HFpEF). Patients with a mid-range ejection fraction
(LVEF 40–49%) or missing LVEF data were not assessed separately.
Analyses were performed using IBM SPSS Statistics version 23. The a
priori significance threshold for all analyses was P < 0.05 using 2-sided
tests.
Results
Patient characteristics
An overview of the cohort is shown in Table 1. A total of 3759
European ancestry individuals from BIOSTAT-CHF were included,
of whom 1976 (53%) had prevalent AF. Mean age was 72.8 ±11.5,
30% were women. These patients were further stratified in 2262
HFrEF patients, of whom 1137 (50.3%) were in sinus rhythm and
1125 (49.7%) had AF; and 530 HFpEF patients, of whom 223 (42%)
were in sinus rhythm and 307 (58%) had AF (Figure 1). Overall,
patients with AF were older (75.0 ± 10.2 vs. 70.3 ± 12.3 years),
more often men (73% vs. 67%), and had a higher body mass index
(28.7 ± 5.9 vs. 28.0 ± 5.9 kg/m2). AF patients more often had renal
disease (38% vs. 29%), but less often had coronary artery disease
(43% vs. 54%) (all P < 0.001).
Genetic risk score and atrial fibrillation
prevalence
In the total cohort, the AF genetic risk score ranged between
4.62 to 8.29 with a median of 6.37. After multivariable adjust-
ment, the odds ratio for AF presence was 2.12 per 1-unit
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Overall (n = 3759) AF (n = 1976, 53%) SR (n = 1783, 47%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age, years 72.8 ±11.5 75.0 ±10.2 70.3 ±12.3 <0.001
Women, n (%) 1128 (30) 537 (27) 591 (33) <0.001
NYHA class I/II/III/IV, % 6/43/36/7 5/46/41/8 8/47/37/8 0.001
Clinical variables
BMI, kg/m2 28.3 ± 5.9 28.7 ± 5.9 28.0 ± 5.9 <0.001
Blood pressure, mmHg
Systolic 125± 22 124± 21 127± 23 0.002
Diastolic 73± 14 73±14 72±13 0.01
Heart rate, bpm 78± 19 80± 21 75±16 <0.001
Medical history, n (%)
Coronary artery diseasea 1814 (48) 856 (43) 958 (54) <0.001
Hypertension 2295 (61) 1221 (62) 1074 (60) 0.32
Diabetes mellitus 1218 (32) 657 (33) 561 (31) 0.25
Renal diseasea 1276 (34) 757 (38) 519 (29) <0.001
Echocardiographic data
LVEF, % 35± 13 36±13 34±13 <0.001
HFrEFb, n (%) 2262 (60) 1125 (57) 1137 (64) <0.001
HFpEFc, n (%) 530 (14) 307 (16) 223 (13) <0.001
Laboratory data
NT-proBNP, ng/L, median (IQR) 2096 (825–4861) 2537 (1128–5122) 1588 (515–4510) <0.001
Medications, n (%)
ACEi/ARB 2681 (71) 1370 (69) 1311 (74) 0.005
Beta-blocker 2410 (64) 1307 (66) 1103 (62) 0.18
MRA 1670 (44) 872 (44) 798 (45) 0.37
Diuretics 3735 (99) 1960 (99) 1775 (99) 0.01
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SR, sinus rhythm.
aCoronary artery disease defined as: previous myocardial infarction, percutaneous coronary intervention and/or coronary artery bypass graft. Renal disease defined as
estimated glomerular filtration rate< 60mL/min/1.73m2.
bHFrEF defined as LVEF <40%.
cHFpEF defined as LVEF ≥50%.
Figure 2 Genetic risk score and risk of atrial fibrillation prevalence. The bars signify the 95% confidence interval, the clear symbols represent
results of model 1 and the solid symbols results of model 2. Squares indicate the total cohort, circles patients with heart failure with reduced
ejection fraction (HFrEF), and triangles patients with heart failure with preserved ejection fraction (HFpEF). Model 1: adjusted for age, sex,
and first 10 principal components of ancestry. Model 2: adjusted for age, height, weight, systolic and diastolic blood pressure, current smoking,
hypertension, diabetes, myocardial infarction, and first 10 principal components of ancestry.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Increasing atrial fibrillation (AF) risk according to genetic risk score tertiles in the total cohort. The bars signify the 95% confidence
interval, the clear symbols represent results of model 1 and the solid symbols results of model 2. Squares indicate the total cohort. Model
1: adjusted for age, sex, and first 10 principal components of ancestry. Model 2: adjusted for age, height, weight, systolic and diastolic blood
pressure, current smoking, hypertension, diabetes, myocardial infarction, and first 10 principal components of ancestry.
Table 2 Proportion of heritability explained by atrial fibrillation loci
Study AF-loci h2g
observed (SE)
AF-loci h2g
liability
scale (SE)
Remaining
genome h2g
observed (SE)
Remaining
genome h2g
liability scale (SE)
Overall h2g
liability scale
Proportion
explained (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
97 AF loci 0.0557 (0.0297) 0.0876 (0.0468) 0.1873 (0.1135) 0.2947 (0.1786) 0.3823 22.92
AF, atrial fibrillation; h2g, single nucleotide polymorphism heritability; SE, standard error.
Proportion of AF single nucleotide polymorphism heritability explained by AF loci, defined as a 1 Mb region around sentinel variants.
increase in genetic risk score (95% CI 1.84–2.45, P = 2.15× 10−24)
in the total BIOSTAT-CHF cohort (Figure 2, Model 2). The
odds ratio were 2.08 per 1-unit increase in genetic risk score
(95% CI 1.72–2.50, P =1.30×10−14) in HFrEF and 2.02 per
1-unit increase (95% CI 1.37–2.99, P = 4.37× 10−4) in HFpEF,
respectively.
There was no interaction between genetic risk score and heart
failure type on AF prevalence (P = 0.99). We estimated odds ratios
comparing individuals in genetic risk score tertiles (Figure 3). The
odds ratio for AF prevalence increased with higher genetic risk
score categories. For the total BIOSTAT-CHF population, those in
the highest tertile had 2.23 fold increased risk of AF compared to
those in the lowest tertile (95% CI 1.87–2.65, P =1.26×10−19).
Heritability and atrial fibrillation
prevalence classification models
Atrial fibrillation-associated loci explain 22.9% of the overall AF
SNP heritability (h2g) in our heart failure sample (Table 2).
The CHARGE-AF risk model had an AUC of 0.699 (95% CI
0.682–0.716) for accurately classifying AF prevalence, and was
better than the genetic risk score alone (AUC 0.606; 95% CI
0.588–0.624). Combining the AF genetic risk score with the
CHARGE-AF risk variables led to a model with an AUC of 0.721
(95% CI 0.704–0.737), a 2.2% increase over the CHARGE-AF risk
model alone (Table 3). .
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Table 3 Area under the receiver operating curves for
atrial fibrillation risk models
Risk model AUC (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHARGE-AF clinical risk
score
0.699 (0.682–0.716) <0.001
AF genetic risk score 0.606 (0.588–0.624) <0.001
CHARGE-AF clinical risk
score+AF genetic risk
score
0.721 (0.704–0.737) <0.001
AF, atrial fibrillation; AUC, area under the receiver operating curve; CI, confi-
dence interval.
Genetic risk score and all-cause
mortality
During follow-up, with a median of 656 days (interquartile range
448–872 days), 1062 patients died (28%). In the total cohort, the
genetic risk score was not associated with an increased risk for
all-cause mortality after multivariable adjustment (HR 0.93, 95%
CI 0.82–1.05, P = 0.22). Similar results were observed for the
HFrEF (HR 0.92, 95% CI 0.78–1.08, P = 0.31) and HFpEF (HR 1.12,
95% CI 0.85–1.48, P = 0.44) subgroups. There was no interaction
between heart failure subgroup and the genetic risk score on
outcome (P = 0.63).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Discussion
In 3759 heart failure patients of European ancestry, an AF genetic
risk score, based on lead SNPs at 97 AF loci, was associated with
a higher prevalence of AF after adjustment for clinical AF risk
variables from the CHARGE-AF risk model. We observed that
22.9% of variance in AF risk was attributable to additive genetic
variation. Furthermore, addition of the AF genetic risk score to
clinical risk factors improved risk model performance in classifying
AF prevalence. The AF genetic risk score was not associated with
all-cause mortality. Our findings support and extend the prior
observation that there is, at least, a partial genetic basis for AF
in patients with HFrEF and HFpEF.12
Genetic basis for atrial fibrillation
in heart failure patients
Atrial fibrillation and heart failure frequently co-exist, but direct
causality has not been unequivocally proven. Additionally, the
underlying mechanisms that lead to the development of AF in
HFrEF and HFpEF and vice versa remain complex and not com-
pletely understood. Previously the ZFHX3 gene was found to be
associated with AF presence in a heart failure population.12 Our
comprehensive AF genetic risk score of 97 SNPs, together with the
estimation that 22.9% of the phenotypic variance is explained by
additive genetic variation, provide evidence of a substantial contri-
bution of genome-wide variation to AF susceptibility in heart failure
patients.
The genetic contribution to AF in our heart failure sample is
less than what was previously observed in population based- and
case-referent AF-GWAS studies, which also included a proportion
of patients with heart failure (approximately 23% vs. 42%). Part
of this portion of missing heritability may be caused by uniden-
tified common genetic variants. Gene–environment interactions
may also play a role, as genetic variants can also have associa-
tions with risk factors (pleiotropic effects). Heart failure patients
have many risk factors including age, hypertension, diabetes, obe-
sity, as well as valvular, ischaemic and non-ischaemic structural
heart disease.10,11 On the other hand, increased cardiac filling pres-
sures and consequently atrial stretch, cardiac fibrosis, dysregula-
tion of intracellular calcium, and autonomic and neuroendocrine
dysfunction in the setting of heart failure may evoke AF. It is pos-
sible that in the context of heart failure, with several concomitant
risk factors, genetics may play a smaller role than in the general
population.
It is hypothesized that AF in the presence of HFrEF is a marker
of more advanced cardiac disease, with ventricular function
deterioration and increased neurohormonal activation, while
patients with AF and HFpEF share a more underlying sub-
strate, albeit heterogeneous, with many shared risk factors.10,11
A difference in the genetic contribution to AF in HFrEF or
HFpEF is not evident from current results, as no interac-
tion between genetic risk score and heart failure type was
observed. ..
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.. Atrial fibrillation genetic risk score
and all-cause mortality
Previous analyses in BIOSTAT-CHF have shown that worse car-
diovascular outcomes were seen in heart failure patients with
AF compared to sinus rhythm.24 Nevertheless, after multivariable
adjustment, the AF genetic risk score was not associated with
all-cause mortality. However, a genetic risk score alone does not
capture the clinical significance of AF presence in patients with
an extensive cardiac substrate and other underlying risk factors.
Additionally, current observations may be affected by survival bias.
Implications
The clinical risk factor model alone outperformed the genetic risk
score, this is to be expected since compared to clinical risk factors
the effect size of genetic variants is small, even when combined in a
polygenic risk score. Although the genetic risk score had moderate
discriminatory accuracy, we demonstrated that a combined risk
model, consisting of the AF genetic risk score with clinical AF
risk factors as present in the CHARGE-AF risk model, performed
better than either risk model alone. But statistical significance does
not automatically translate into clinical significance, and currently
translation of genetics into clinical practice remains unresolved.
In the future, genetic profiling may provide insight into the
mechanisms that underlie why some patients develop AF and
others do not. The individual SNPs implicate genes that may reveal
some of the mechanisms underlying AF (online supplementary
Figure S1).13 Currently, most genes represent gene candidates
at the loci, while the causal gene remains unknown. Experimen-
tal observations illustrate the pleiotropic nature of genes that
are associated with this challenging arrhythmia and underscore
the complexity of AF: so does PITX2 encodes a transcription
factor that plays a role in the formation of the pulmonary vein
myocardium,25 does TBX5 encodes transcription factors that are
required for patterning and maturing of the cardiac conduction
system in mice26 and have KCNN3 and SCN5A, which both encode
subunits of the potassium channel complex, been previously been
linked to AF through candidate gene analyses and family-based
studies.27 More insights into the functional consequences of SNPs
and genes is critical to identify potential therapeutic targets for this
major health burden.28 However, whether the genetic proportion
to AF risk has a meaningful contribution to clinical risk assessment
warrants further investigation.
Limitations
Current results, based on genetic data of 97 SNPs in 3759 patients
from a well-defined heart failure cohort, point towards a genetic
basis for AF in the context of heart failure. Analyses were limited to
European ancestry individuals, and the current heart failure sample
had a higher percentage of men with only 30% of women, and a
higher percentage of HFrEF than is typical in the community; the
findings may not be completely generalizable to individuals of dif-
ferent ancestral backgrounds, regions, or the general heart failure
population. Additionally, women and men generally have a different
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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risk factor burden, which next to genetics and the underlying heart
failure substrate, may be of different importance in the presence of
concomitant heart failure and prevalent AF. Second, the genetic risk
models were linear in nature with a single predictor variable and
did not account for potential non-additive genetic effects, interac-
tions between genetic variants, or interactions between genetic
variants and environmental factors. Therefore, all observations
are vulnerable to the risk of residual confounding that may bias
mentioned estimates. Thirdly, AF ascertainment was partially based
on physician-reported AF. This means that the percentage of AF is
likely an underestimation since subclinical AF may have gone unde-
tected. Fourthly, whether heart failure developed before the onset
of AF, or AF before the onset of heart failure may be associated with
a different genetic risk. Also the sequence in which the diseases
develop can impact outcome. Unfortunately, we did not have infor-
mation on the onset of AF and heart failure; therefore a temporal
sequence of diagnoses was unknown, prohibiting time-dependent
analyses. AF occurrence during follow-up was not systematically
collected and therefore current analyses focus on baseline AF
prevalence. Additionally, there was a lack of data on type and dura-
tion of AF, as well as applied therapies for AF. Fifthly, electro- and
echocardiographic variables such as left atrial volume were omitted
from the models since they were not available in a large propor-
tion of patients. Additionally, these biomarkers will be influenced by
both the underlying heart failure substrate as well as AF presence,
duration, and severity. Covariates including LVEF, New York Heart
Association class and NT-proBNP will be confounded by AF itself
as it inhibits adequate echocardiographic determination of ejec-
tion fraction, is associated with symptoms of dyspnoea, and will
lead to an increase in NT-proBNP levels. In line with the previous
limitation, we did not adjust for heart failure severity in the mul-
tivariable models. We acknowledge that the CHARGE-AF model
application in heart failure was not ideal, albeit the best validated
AF risk score. Sixthly, in determining SNP heritability we assessed
variants with MAF ≥1%, and, therefore, the contribution of rare
or loss-of-function variants to total AF variance was not assessed.
Furthermore, the estimates for SNP heritability have large standard
errors bringing a level of uncertainty to these estimates. Seventhly,
we cannot attribute the AF risk variance to functional categories.
It remains challenging to identify the causal gene at each locus
since the AF-associated SNPs predominantly fall within non-coding
portions of the genome. Additionally, the association of genes to
functional groups is based on their affiliation to enriched gene sets
that were identified in an in silico analysis. Lastly, establishing a heart
failure cohort of sufficient size is complex, and the current study
is underpowered to study individual SNPs or perform extensive
subgroup analyses. Larger studies, powered for outcomes, are war-
ranted to investigate the genetic contribution to incident AF in
heart failure populations, both HFrEF and HFpEF. Further efforts
are needed to uncover the functional consequence of SNPs and
genes at each locus on AF risk in patients with incident heart failure.
Conclusion
The AF genetic risk score was associated with increased AF
prevalence in heart failure patients with reduced and preserved ..
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.. ejection fraction. Genetic variation accounted for 22.9% overall
AF SNP heritability. Addition of the AF genetic risk score to
clinical risk factors improved risk model performance in classifying
AF prevalence. Efforts are warranted to consider the role and
mechanisms of genetic susceptibility of AF risk in heart failure
patients.
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. SNPs and weights used in the AF genetic risk score.
Figure S1. Venn diagram.
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